| Name | Title | Contact Details |
|---|---|---|
Michelle Kruse |
Senior Director Talent & Development | Profile |
Erin Picchi |
Director, HR Operations and Employee Relations | Profile |
Stacey Harte |
Vice President, Global Product Lead | Profile |
Nancy Lundy |
Vice President of People and Culture | Profile |
Myrexis, Inc. is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Enzymerx is a Paramus, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The future is different. We are building sensing and thinking machines, with synthetic neurobiology at its core. Machines with extremely dense sensing and computation based on carbon. In our systems, everything can be engineered with care for sustainab...
Cerus Corporation is dedicated solely to safeguarding the world`s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.